NCT02076620View on ClinicalTrials.gov

L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 16, 2013

Primary Completion Date

January 25, 2018

Study Completion Date

January 25, 2018

Conditions
Advanced Solid Tumors Amenable to Anthracycline TherapySarcoma, Breast Cancer, Lung Carcinomas, and Gynecological Cancer Amenable to Anthracycline Therapy
Interventions
DRUG

L19TNFα

L19TNFα will be administered as a 2 hours i.v. infusion on days 1, 3, and 5 of each 3-week cycle.

DRUG

Doxorubicin

Doxorubicin will be administered as a 15 minutes i.v. infusion on day 1 of each 3-week cycle prior L19TNFα administration.

Trial Locations (2)

Unknown

Universitätsklinikum Münster, Münster

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

All Listed Sponsors
lead

Philogen S.p.A.

INDUSTRY

NCT02076620 - L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours | Biotech Hunter | Biotech Hunter